Xenon Pharmaceuticals Inc. (XENE) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy, depression, and pain. The company has no approved products and relies on equity financing and collaboration agreements to fund operations. As of May 4, 2026, there were 96,665,550 common shares outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $0 | $7,500 |
| Net Loss | $(102,302) | $(65,047) |
| Net Loss Per Share (Basic & Diluted) | $(1.17) | $(0.83) |
| Research & Development Expenses | $88,508 | $61,200 |
| General & Administrative Expenses | $23,820 | $19,038 |
| Cash and Cash Equivalents (End of Period) | $545,867 | $116,657 |
| Total Cash, Equivalents & Marketable Securities | $1,339,621 | $586,038 |
| Accumulated Deficit | $(1,347,682) | $(964,517) |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped to $0 from $7.5 million in Q1 2025. The prior period revenue was a one-time milestone payment from Neurocrine Biosciences related to the NBI-921355 program.
- Increased Losses: Net loss increased by approximately 57% to $102.3 million, driven by higher R&D spending and the absence of milestone revenue.
- R&D Spend Surge: R&D expenses rose by $27.3 million (45% increase), primarily due to ongoing Phase 3 clinical studies for azetukalner in epilepsy and depression, and Phase 1 studies for pain programs.
- Capital Raise: The company significantly strengthened its balance sheet through equity financing. In Q1 2026, it raised approximately $837.5 million net from an underwritten public offering and ATM sales, compared to minimal financing activity in Q1 2025.
- Liquidity Improvement: Total cash and marketable securities more than doubled to $1.34 billion, providing a runway for at least the next 12 months.
Guidance, Outlook, and Management Commentary
- Azetukalner Progress: Management announced positive topline data from the Phase 3 X-TOLE2 study for focal onset seizures (FOS) in March 2026. The study met its primary endpoint with a placebo-adjusted median percent change of -42.7% in the 25 mg group. An NDA submission to the FDA is anticipated in Q3 2026.
- Depression Programs: Enrollment is ongoing for Phase 3 studies in Major Depressive Disorder (MDD) and Bipolar Depression (BPD). Topline data for MDD is expected in H1 2027.
- Pipeline Expansion: Phase 1 studies for pain candidates XEN1701 (Nav1.7) and XEN1120 (Kv7) are ongoing, with completion expected in H2 2026.
- Financial Outlook: The company expects to continue incurring significant operating losses for the foreseeable future as it prepares for the potential commercial launch of azetukalner and advances other candidates. No product revenue is expected until regulatory approval is obtained.
- Risks: Key risks include the unpredictability of clinical trial outcomes, regulatory approval timelines, patient enrollment challenges, and the need for future capital raises if current resources are depleted faster than anticipated.
Investor Verification Checklist
- NDA Submission Timeline: Verify the specific date and regulatory feedback for the anticipated Q3 2026 NDA submission for azetukalner in FOS.
- Runway Analysis: Confirm the burn rate against the $1.34 billion cash position to validate the "12-month" liquidity statement, considering the high R&D spend trajectory.
- Phase 3 Enrollment: Monitor enrollment rates for the ongoing X-NOVA2 (MDD), X-NOVA3 (MDD), and X-CEED (BPD) studies to assess the risk of delays.
- Dilution Impact: Review the impact of the recent equity offering (12.2 million shares + pre-funded warrants) on existing shareholder ownership and future dilution potential.
- Collaboration Milestones: Track the status of the Neurocrine Biosciences collaboration for future milestone triggers, as this was the sole revenue source in the prior year.